Table 3.
Characteristics of mRCC cases of extrapulmonary metastasis involving molecular targeted therapy
| Pretreated NLR | Total | |||
|---|---|---|---|---|
|
| ||||
| Low (≤3.0) | High (>3.0) | p | ||
| No. of patients | 111 | 79 | 190 | |
| Age, range (median) | 40–85 (64) | 47–85 (67) | 0.0762 | 40–85 (65) |
| Gender, n (%) | ||||
| Male | 96 (86.5) | 65 (82.3) | 0.4267 | 161 (84.7) |
| Female | 15 (13.5) | 14 (17.7) | 29 (15.3) | |
| Histological type, n (%) | ||||
| Clear | 92 (82.9) | 65 (82.3) | 0.9137 | 157 (82.6) |
| Non-clear | 19 (17.1) | 14 (17.7) | 33 (17.4) | |
| ECOG performance status, n (%) | ||||
| 0 | 87 (78.4) | 57 (72.2) | 0.3234 | 144 (75.8) |
| ≥1 | 24 (21.6) | 22 (27.8) | 46 (24.2) | |
| Anemia, n (%) | ||||
| (−) | 58 (52.3) | 59 (74.7) | 0.0017 | 117 (61.6) |
| (+) | 53 (47.7) | 20 (25.3) | 73 (38.4) | |
| Hypercalcemia, n (%) | ||||
| (−) | 109 (98.2) | 71 (89.9) | 0.0113 | 180 (94.7) |
| (+) | 2 (1.8) | 8 (10.1) | 10 (5.3) | |
| LDH (%) | ||||
| ≤1.5 x ULN | 105 (94.6) | 69 (87.3) | 0.0760 | 174 (91.6) |
| > 1.5 x ULN | 6 (5.4) | 10 (12.7) | 16 (8.4) | |
| Metastatic organs, n (%) | ||||
| 1 | 41 (36.9) | 26 (32.9) | 0.5671 | 67 (35.3) |
| ≥2 | 70 (63.1) | 53 (67.1) | 123 (64.7) | |
| Prior nephrectomy, n (%) | ||||
| Yes | 102 (91.9) | 64 (81.0) | 0.0261 | 166 (87.4) |
| No | 9 (8.1) | 15 (19.0) | 24 (12.6) | |
| Targeted agents, n (%) | ||||
| TKI | 85 (76.6) | 57 (72.2) | 0.4891 | 142 (74.7) |
| mTOR inhibitor | 26 (23.4) | 22 (27.8) | 48 (25.3) | |
| Timing of treatment, n (%) | ||||
| First-line | 42 (37.8) | 34 (43.0) | 0.4708 | 76 (40.0) |
| Second-line or later | 69 (62.2) | 45 (57.0) | 114 (60.0) | |
ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase; mRCC: metastatic renal cell carcinoma; NLR: neutrophil-to-lymphocyte ratio; TKI: tyrosine kinase inhibitor; ULN: upper limits of normal.